

## Triple-Negative Breast Cancer: Focus on Diagnosis, Therapy, Prognosis

Guest Editor(s)



**Associate Prof. Guan Wang**

West China Hospital, Sichuan University, China

**Interests:** Breast Cancer; Targeted Small Molecule Drug; Drug Discovery; Pharmacology; Traditional Chinese Medicine; Medicinal Chemistry; Precision Nursing

**Email:** [guan8079@163.com](mailto:guan8079@163.com)



**Associate Prof. Lan Zhang**

School of Life Science and Engineering, Southwest Jiaotong University, China

**Interests:** Breast Cancer; Targeted Small Molecule Drug; Drug Discovery; Drug Repurposing; Pharmacology; Medicinal Chemistry

**Email:** [zhanglanx\\_9@126.com](mailto:zhanglanx_9@126.com); [zhanglan299@swjtu.edu.cn](mailto:zhanglan299@swjtu.edu.cn)



**Associate Prof. Jin Zhang**

School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, China

**Interests:** Breast Cancer; Tumor Biological Target Identification; Oncology Pharmacology; Targeted Small Molecule Drug

**Email:** [zhangjin1989@szu.edu.cn](mailto:zhangjin1989@szu.edu.cn); [zhangjinjin8916@163.com](mailto:zhangjinjin8916@163.com)

Dear Colleagues,

As a special molecular subtype of breast cancer, Triple-Negative Breast Cancer (TNBC) refers to breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) amplification. Accounting for approximately 15% of breast cancer, TNBC has special molecular expression characteristics, biological behavior and clinicopathological characteristics, which manifested as relatively young onset, strong aggressiveness, high risk of early recurrence and high rate of distal metastasis. At present, conventional chemotherapy and radiotherapy and surgical excision are mostly used in the treatment of TNBC, but the therapeutic effect is still not satisfied with expectations. In recent years, with the deepening of basic research on TNBC, more and more targeted therapy and molecular mechanisms related to biotherapy have been revealed, such as the synthetic lethality of BRCA1/2 and PARP, PI3K/AKT/mTOR pathway, PD-1/PD-L1, etc. The continuous exploration of the pathogenesis of TNBC provides promising strategies and methods for the diagnosis, clinical treatment, nursing practice and prognosis of TNBC.

We accept manuscripts related to TNBC diagnosis, treatment, and prognosis. Equally important, we also invite researchers to share their recent discovery and validation of TNBC-related targets and related therapeutic entities, including traditional Chinese medicine and small molecule drugs.

**Key Words:** Triple-Negative Breast Cancer; Small Molecule Drug; Traditional Chinese Medicine; Epidemiological Investigation; Diagnosis; Therapy; Prognosis

**Submission Deadline:** 01 February 2023

**Online Submission System:** <https://js.ejgo.net/ch/author/login.aspx>

<https://www.ejgo.net/>